ArticleInflammatory bowel diseases2011
Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior.
Article in Inflammatory bowel diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 82 citations in OpenAlex.
- Serological profiling of Crohn's disease and ulcerative colitis patients reveals anti-microbial antibody signatures.World journal of gastroenterology · 2022Trial
- A high-fiber diet may improve bowel function and health-related quality of life in patients with Crohn disease.Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and AssociatesTrial
- Anti-OmpC antibodies in Crohn's disease and ulcerative colitis: evidence from a systematic review and meta-analysis.Crohn's & colitis 360 · 2026Article
- Serological Markers as Predictors of Anti-TNF Response in Children with Crohn's Disease.Digestive diseases and sciences · 2025Article
- Delayed diagnosis in inflammatory bowel disease: Time to consider solutions.World journal of gastroenterology · 2024Article
- A promising natural killer cell-based model and a nomogram for the prognostic prediction of clear-cell renal cell carcinoma.European journal of medical research · 2024Article
- Apolipoprotein E variants correlate with the clinical presentation of paediatric inflammatory bowel disease: A cross-sectional study.World journal of gastroenterology · 2021Article
- Association Between Serological Markers and Crohn's Disease Activity.Journal of clinical medicine research · 2020Article
- Living With Inflammatory Bowel Disease: Protocol for a Longitudinal Study of Factors Associated With Symptom Exacerbations.JMIR research protocols · 2018Article
- Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.Gastroenterology · 2018Article
- New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes.Inflammatory bowel diseases · 2016Review
- B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.Digestive diseases and sciences · 2016Review
- Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.Therapeutic advances in gastroenterology · 2016Review
- A Personalized Approach to Managing Inflammatory Bowel Disease.Gastroenterology & hepatology · 2016Article
- Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic Perspective.Molecular & cellular proteomics : MCP · 2016Article
- Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.Gastroenterology · 2015Review
- The use of prognostic factors in inflammatory bowel diseases.Current gastroenterology reports · 2014Review
- Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients.Inflammatory bowel diseases · 2014Article
- Increased prevalence of luminal narrowing and stricturing identified by enterography in pediatric Crohn's disease patients with elevated granulocyte-macrophage colony stimulating factor autoantibodies.Inflammatory bowel diseases · 2013Article
- The role of the innate and adaptive immune system in pediatric inflammatory bowel disease.Inflammatory bowel diseases · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundTreatment of Crohn's disease (CD) with biologics may alter disease progression, leading to fewer disease-related complications, but cost and adverse event profiles often limit their effective use. Tools identifying patients at high risk of complications, who would benefit the most from biologics, would be valuable. Previous studies suggest that biomarkers may aid in determining the course of CD. We aimed to determine if combined serologic immune responses and NOD2 genetic markers are associated with CD complications.
methodsIn this cross-sectional study, banked blood from well-characterized CD patients (n = 593; mean follow-up: 12 years) from tertiary and community centers was analyzed for six serological biomarkers (ASCA-IgA, ASCA-IgG, anti-OmpC, anti-CBir1, anti-I2, pANCA). In a patient subset (n = 385), NOD2 (SNP8, SNP12, SNP13) genotyping was performed. Complications included stricturing and penetrating disease behaviors. A logistic regression model for the risk of complications over time was constructed and evaluated by cross-validation.
resultsFor each serologic marker, complication rates were stratified by quartile. Complication frequency was significantly different across quartiles for each marker (P trend ≤ 0.001). Patients with SNP13 NOD2 risk alleles experienced increased complications versus patients without NOD2 mutations (P ≤ 0.001). A calibration plot of modeled versus observed complication rates demonstrated good agreement (R = 0.973). Performance of the model integrating serologic and genetic markers was demonstrated by area under the receiver operating characteristic curve (AUC = 0.801; 95% confidence interval: 0.757-0.846).
conclusionsThis model combining serologic and NOD2 genetic markers may provide physicians with a tool to assess the probability of patients developing a complication over the course of CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.